BIX-01294 and its analogs were originally identified and subsequently designed as potent inhibitors against histone H3 lysine 9 (H3K9) methyltransferases G9a and G9a-like protein (GLP).
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The Jumonji domain containing protein (histone) lysine demethylases are members of the cupin family of α-ketoglutarate (α-KG) and Fe 2+ dependent dioxygenases 1 . There are nearly 30 Jumonji containing proteins with known or suggested lysine demethylation function in human proteome 2 . Abnormal activities of many of these enzymes have been implicated in various pathological conditions like cancer, developmental and neurological disorders 3; 4 . Thus, these enzymes are novel targets for therapeutics 5; 6; 7 .
Currently known inhibitors of Jumonji demethylases resemble the chemical structure of αketoglutarate, the cofactor, or succinate, which is the byproduct generated during enzymatic decarboxylation of α-ketoglutarate 8; 9; 10 . Consequently, the cofactor-mimic compounds could inhibit a large numbers of α-ketoglutarate dependent dioxygenases by competing for the cofactor-binding sites.
BIX-01294 (a diazepin-quinazoline-amine derivative; Fig. 1a ) inhibits activities of G9a 11 and G9a-like protein (GLP) lysine methyltransferase by mimicking the bound conformation of histone H3 Lys4 to Arg8, residues N-terminal to the target lysine 9 of histone H3, in the substrate peptide-binding groove 12 . Addition of a lysine or methyl-lysine mimic to BIX-01294 enhances its potency of inhibition of G9a and GLP due to the insertion of the mimics into the target lysine-binding channel 13; 14; 15; 16 . It is interesting to note that both lysine methyltransferases and demethylases recognize lysines in methylated and unmethylated states, whether they are substrates or reaction products. We therefore explore whether BIX analogs can function as selective inhibitors of human KIAA1718 (a H3K9me2 demethylase, also known as JHDM1D), in comparison with their inhibitions of human GLP (a H3K9 methyltransferase, also known as EHMT1) -whose loss-of-function mutations cause the 9q34 subtelomeric deletion syndrome 17 -and human JARID1C (a H3K4me3 demethylase, also known as SMCX) -mutations of which affect its demethylase activity are found in X-linked mental retardation patients 18; 19 .
KIAA1718 belongs to a small family of Jumonji proteins with three members (PHF2, PHF8 and KIAA1718) 2 . Each of these proteins harbors two domains in its respective N-terminal half ( Supplementary Fig. S1a ): a PHD domain that binds tri-methylated histone H3 lysine 4 (H3K4me3) -a modification associated with transcriptional activation -and their linked Jumonji domains which remove methyl marks (H3K9me2, H3K27me2, or H4K20me1) that are associated with transcriptional repression 20; 21; 22 . KIAA1718 removes methyl marks from dimethylated H3 lysine 9 (H3K9me2) and/or lysine 27 (H3K27me2) 20; 23; 24 , which shares an ARKS sequence. Here, we focus on residues 92-488 from KIAA1718 (Jumonji) and 1-488 (containing PHD and Jumonji) ( Supplementary Fig. S1b ).
Inhibition of KIAA1718 by BIX and its analog E67
First, we found BIX-01294 inhibits the demethylation activity of KIAA1718 Jumonji domain (residues 92-488) with an IC 50 (half-maximal inhibitory concentration) value of approximately 16.5 µM, using a histone H3K9me2 peptide (residues 1-24) as substrate, by a mass spectrometry-based demethylation assay 20 (Fig. 1a ). Next, we tested the BIX analog E67 (Fig. 1b) , which was originally generated with improved inhibition for GLP 14 , with the replacement of the O7-methoxy group with a 5-aminopentyloxy substituent at site A and the diazepane ring with a 3-dimethylaminopropyl group at site B. The cumulative effect of these changes in E67 decreases its IC 50 by a factor of approximately 4.5 in comparison to that of BIX.
Structure of KIAA1718 Jumonji domain bound with E67
We co-crystallized KIAA1718 Jumonji domain with E67, which was dissolved in aqueous buffer, in the presence of α-ketoglutarate and Ni 2+ ion ( Supplementary Fig. S1c ). The structure was solved at a resolution of 2.8 Å ( Table 1 ). The first 22 residues (amino acids 92-113) and the last 9 residues (amino acids 480-488) of KIAA1718 were not observed. The protein component of the structure is highly similar to that of KIAA1718 in the absence of bound peptide substrate ( Fig. 2a ; PDB 3KVA) and that of PHF8 in the presence of bound H3 peptide substrate ( Fig. 2c ; PDB 3KV4), with a root mean squared deviation (rmsd) of approximately 0.3 Å and 1.3 Å, respectively, when comparing 366 pairs of Cα atoms (residues 114-479).
E67 lies in a location occupied by the histone H3 peptide in the PHF8-peptide complex (compare Fig. 2b with Fig. 2c ). E67 occupies approximately the same space as that by histone H3 lysine 4 (main chain) to lysine 9 ( Fig. 2d) , with a total of buried interface area of 422 Å 2 . The acidic binding pocket is wide open and the α-ketoglutarate can be seen at the bottom of the pocket (Fig. 2e ). The 5-aminopentyloxy moiety at site A is extended near the metal cofactor in the active site, with the aliphatic chain stacking with the planar surface of His282 and the terminal amino group forming a weak hydrogen bond with one of the carboxyl oxygen atoms of Asp284 (3.4 Å) ( Fig. 2f ). The side chains of His282 and Asp284, together with His354, coordinate the binding of the metal ion. The N,Ndimethylpropylamine side chain at site B is near the acidic entrance of the substrate binding groove on the protein surface ( Fig. 2e ) and the terminal dimethylated amino group folds back and stacks with the planar surface of the quinazoline ring (Fig. 2f ).
The methyl group of the O6 methoxy at site D is inserted into a shallow surface pocket of an inner wall formed by Gln200 and Thr279 (Fig. 2g ), mimicking the side chain of histone H3 Ala7 (H3A7; Fig. 2d ). The O6 methyoxy-H3A7 mimic has also been observed in the interactions of E67 as well as BIX with GLP methyltransferase 12; 14 . Thus, we suggest the O6 methyoxy at site D is an important discriminator of H3K9 enzymes (methylase and demethylases) vs. H3K4 enzyme(s) (see below). The N-benzyl-4-amino-piperidine moiety at site C is not observed in the structure. We could however model the moiety in the current structure without steric clashes with the protein by pointing the moiety to the solvent ( Supplementary Fig. S1d ).
Generation of compound E67-2
Based on the structural information of KIAA1718-E67 complex, we thus generated a smaller compound (E67-2) without the N-benzyl-4-amino-piperidine moiety. E67-2 inhibits KIAA1718 Jumonji domain with an IC 50 value of 3.4 µM ( Fig. 1c) , the same as that of E67 ( Fig. 1b ). Removal of both of the side chains at sites B and C (compound E67-5) increases the IC 50 value by a factor of approximately 5 (Fig. 1d ). Compounds E67 and E67-2 retain the inhibitory potency towards related PHF8 Jumonji domain ( Fig. 1e ).
Compound E67 was originally designed to improve the potency against H3K9 methyltransferase activities of G9a and GLP (with an IC 50 value of 50 nM; Fig. 1f ) 14 . Unexpectedly, the new E67 derivative (E67-2) reduced inhibitory effect against GLP by a factor of approximately 1500, resulting in an IC 50 of 75 µM (Fig. 1f ).
Effect of PHD domain on the activity of Jumonji domain
KIAA1718 and PHF8 have a N-terminal H3K4me3-binding PHD domain linked to their respective catalytic Jumonji domain ( Fig. 3a) {Horton, 2010 #919}. The inhibition (under the same assay conditions) for the KIAA1718 (residues 1-488), including both the PHD and Jumonji domains, is comparable to those measured for the Jumonji domain only (residues 92-488) ( Fig. 3b ), suggesting that the PHD domain of KIAA1718 has minor influence on the inhibitory properties of these compounds that target the Jumonji active site. On the other hand, while retaining the inhibitory potency towards related PHF8 Jumonji domain ( Fig. 1e and Fig. 3c , top panel), compounds E67 and E67-2 have much reduced inhibition on PHF8 (residues 1-447) on the doubly methylated H3(1-24)K4me3K9me2 peptide substrate (Fig.  3c, bottom panel) . This can be explained by the structural observation that KIAA1718 has an extended conformation between the two domains that allows the compound to be diffused into the active site, whereas PHF8 has a closed conformation, which limits the access to the Jumonji active site when its PHD domain engages H3K4me3 (Fig. 3a ). Removal of the Nterminal PHD domain from the protein (Fig. 3c, top panel) or the H3K4me3 mark from the substrate (Fig. 3c , middle panel) renders these inhibitors more effective in inhibiting H3K9me2 demethylation activity of PHF8, indicating that binding of the H3K4me3 mark by the PHD domain impairs the inhibitor binding to the active site (Fig. 3c , bottom panel).
Selectivity over JARID1C, an H3K4me3 demethylase
We next tested whether the current inhibitors (E67 and E67-2) against KIAA1718 and PHF8 (two related H3K9me2 demethylases) can also inhibit H3K4me3 demethylation activity of JARID1C enzyme ( Supplementary Fig. S2a ). We purified the N-terminal half of JARID1C (residues 1-839) containing the catalytic Jumonji domain ( Supplementary Fig. S2b ). The JARID1C is an active H3K4me3 demethylase, with an optimum pH at 6.5-6.8 ( Supplementary Fig. S2c ) and maximal activity at 50 mM NaCl ( Supplementary Fig. S2d ). The demethylation activity is also dependent on substrate H3 peptide length and is active on peptide longer than 12 amino acids ( Supplementary Fig. S2e ).
We used a fluorescence-based demethylation assay based on a formaldehyde dehydrogenase-coupled continuous reaction 20 to determine the kinetic characteristics of JARID1C. We determined the K M for α-ketoglutarate to be approximately 5 µM (Fig. 4a) , and K M for peptide substrate approximately 3 µM (under the conditions of α-ketoglutarate concentration being 200 µM, at which reaction velocity is well saturated) (Fig. 4b) . The turnover rate (K cat ) of JARID1C is approximately 2.5 ~ 3 min −1 , which is significantly faster than most known Jumonji histone lysine demethylases (comparing K cat ~ 0.1 min −1 for PHF8 and KIAA1718 20 and K cat ~ 0.01-0.07 min −1 for JMJD2A and JMJD2D 25 ).
As evident from the activity data ( Fig. 4c ), neither BIX nor its analogs (E67 and E67-2) can significantly inhibit JARID1C demethylation activity on the H3K4me3 peptide substrates. This is consistent with the fact that recognition of H3K4 and H3K9 methylation marks involves different sets of backbone and side chain interactions and the BIX analogs tested in this work are originally designed to mimic H3K9 binding.
Finally, we tested the cell toxicity of the three compounds in mouse and human primary fibroblasts. Like E67 14 , E67-2 has significantly reduced cell toxicity in vivo (Fig. 5) , compared with BIX, in all four types of mouse and human primary fibroblasts treated. For E67-2, the LC 50 (half-maximal lethal concentration) values are 45.8 µM in mouse cells and 52.1 µM in human cells, respectively, comparable to that of E67 (24.1 µM for mouse cells and 95.6 µM for human cells) but much higher than that of BIX-01294 (7.4 µM for mouse cells and 3.2 µM human cells).
Discussion
Here we show that BIX-01294, a H3K9 peptide mimic small molecule compound, can inhibit both H3K9 methyltransferase (GLP: IC 50 = 0.25 µM; Fig. 1f ) and demethylase (KIAA1718: IC 50 =16.5 µM; Fig. 1a ). Because the IC 50 values are enzyme concentration dependent, we thus compared K i app Copeland (2005) 26 for the two H3K9 modifying enzymes (Fig. 1g ). Both BIX and E67 inhibit GLP better than KIAA1718 by a factor of approximately 76 (comparing K i app values of 0.2 vs. 15.3 µM) and 2500 (0.001 vs. 2.5 µM), respectively. By deleting the benzylated six-membered piperidine ring moiety, as suggested by the co-crystal structure of KIAA1718-E67 complex, E67-2 is more selective against KIAA1718 than GLP by a factor of 35 (comparing K i app values of 2.1 vs. 75 µM). This reversal of selectivity is only due to the severe loss in activity against GLP without affecting inhibition against KIAA1718. Therefore, the current structure of KIAA1718-E67 complex provides new avenues for further improving the potency and selectivity of the inhibitor by strengthening KIAA1718-E67 interactions. For example, the N,N-dimethylpropylamine side chain at site B has little contact with the protein and replacement with group(s) that maximize the interaction near the entrance of the substrate binding groove may increase the potency against KIAA1718. Iterative cycles of crystallography, synthesis, and bioassay will ultimately aid successful design of selective and potent epigenetic inhibitors of histone lysine demethylases.
Synthesis of compounds
E67 has been prepared as previously reported 14 . For E67 derivatives ( Supplementary Fig.  S3 ), the anthranilic 
Crystallography
The X-ray diffraction data (Table 1) were collected at the Advanced Photon Source, Argonne National Laboratory, SERCAT beamline (22-BM). Diffraction data were processed and scaled by HKL2000 27 . We used PHENIX 28 for molecular replacement, using a previously solved KIAA1718 (residues 92-488) structure (PDB 3KVA) 20 as the initial model, and refinement. Coot 29 was used for graphic model building. PRODRG server 30 generated the initial model of E67 compound. The ReadySet software integrated in PHENIX generated the structural restraints for the inhibitor molecule. PyMOL (DeLano Scientific) was used to prepare the structural figures.
Highlights
• BIX-01294 inhibits both H3K9 methyltransferase and H3K9 Jumonji demethylase
• E67-2 selectively inhibits H3K9 Jumonji demethylase over H3K9 methyltransferase as well as H3K4 demethylase
• E67-2 has low cytotoxicity
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